Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
14 cost-effectiveness analyses and 10 studies reporting utility weights · 14 sources
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 14 |
| Studies reporting utility weights | 10 |
Cost-effectiveness analyses
Analyses of Hibsago (bepirovirsen and GSK3228836)
No evidence found.
Treatments for the same indication
Tenofovir disoproxil fumarate, entecavir, tenofovir alafenamide, and pegylated interferon as first-line treatment in chronic hepatitis B, China: Dai et al. (2022)
Relevance: Evaluates first-line tenofovir disoproxil fumarate, entecavir, tenofovir alafenamide, and pegylated interferon in chronic hepatitis B in China, covering the nucleos(t)ide analogues and the pegylated interferon alfa listed in section 2 as current treatment options.
Access: Free full text
Entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide versus best supportive care in chronic hepatitis B, China: Lin et al. (2025)
Relevance: Evaluates entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide against best supportive care in chronic hepatitis B in China, the nucleos(t)ide analogue therapy that continued as background treatment in both arms of the B-Well 1 and B-Well 2 trials.
“A cost-utility analysis was performed, considering direct medicine costs and health utility background.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A Markov model simulated a hypothetical cohort of 100,000 Chinese CHB patients aged 14 years, meeting Chinese guideline criteria for hepatitis B treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The model spanned a lifetime horizon of 64 years, aligning with the Chinese life expectancy of 78 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were converted from Chinese Yuan (CNY) to US dollars (USD) at an average exchange rate of 7.3:1 (CNY: USD) in 2023. Both costs and QALYs were discounted annually at a rate of 5%, following China’s Guidelines for Pharmacoeconomic Evaluations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In comparison to Non-NAs BSC, TAF yielded an additional 2.68 QALYs per person, with an ICER of 7,853.22 USD/QALY. Subsequently, TDF generated an additional 2.61 QALYs/person at an ICER of 7,153.39 USD/QALY, and ETV produced an additional 2.01 QALYs/person with an ICER of 9,366.74 USD/QALY without NVBP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incorporating NVBP, the ICERs for TAF, TDF, and ETV decreased to −745.62 USD/QALY, −729.33 USD/QALY, and −871.11 USD/QALY, respectively, compared to non-NAs BSC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At willingness-to-pay (WTP) thresholds ranging from 12,500 USD/QALY to 37,500 USD/QALY, TAF with NVBP showed an increased probability (51.15–52.47%) of being the optimal treatment strategy, followed by TDF and ETV with NVBP exhibiting a reduced likelihood 43.09–42.45% and 6.40–4.48% in the iterations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tenofovir alafenamide versus entecavir in chronic hepatitis B, Taiwan: Lai et al. (2024)
Relevance: Compares tenofovir alafenamide with entecavir in chronic hepatitis B in Taiwan from a payer perspective, nucleos(t)ide analogues that make up the background therapy of the bepirovirsen label population.
“We performed inverse probability of treatment weighting (IPTW) to match the independent variables between the two treatment groups. The incremental cost effectiveness ratio (ICER) of the two treatment groups was simulated using a decision tree with the Markov annual-cycle model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 54 patients treated with TAF and 98 with ETV from January 2016 to December 2020 were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was a payer’s perspective pharmacoeconomic study, and data involving the direct medical cost were retrieved from the health insurance claims of the National Health Insurance Research Database (NHIRD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to local clinical experience, we set one cycle at one year and the research time horizon at 30 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each cost structure was adjusted to the present value in 2021 according to Taiwan’s consumer price index (CPI), and the cost and quality-adjusted life years (QALYs) in the decision-making model were discounted at a rate of 2%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within this temporal framework, the total costs for individuals within the TAF group were registered at NT$1,241,822, corresponding to an effectiveness of 14.63 QALYs. In contrast, the ETV group incurred total costs of NT$1,317,920, accompanied by an effectiveness of 11.44 QALYs (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the time horizon was set at 30 years, the ICER of the TAF group compared with the ETV group was −NT$23,878 per QALY, suggesting more cost savings for TAF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, the CUAC revealed that when the WTP was between NT$0 and NT$990,120, the probability for the TAF group being more cost effective than the ETV group was 100% (Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extended-duration nucleoside analogue and pegylated interferon alfa combination versus nucleoside analogue monotherapy in HBeAg-negative chronic hepatitis B, China: Li et al. (2021)
Relevance: Evaluates extended-duration combination antiviral treatment against nucleos(t)ide analogue monotherapy in HBeAg-negative chronic hepatitis B in China, an add-on strategy to background nucleos(t)ide analogue therapy whose model includes an HBsAg health state.
“Drawing on experience in China, we used a Markov model to simulate disease progression among a population of hepatitis B e antigen-negative chronic hepatitis B patients with surface antigen levels of ≤1,000 IU/mL through a discrete series of health states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The model’s time horizon was 50 years, with a cycle length of 1 year, and patients from the initial state could either move to another state or remain in the same state after a 1-year cycle. A half-cycle correction was applied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were converted to 2018 values in USDs using an exchange rate of 1 USD =6.6174 Chinese Yuan. The discount rate was determined to be 5% per annum” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination therapy produced 15.8 quality-adjusted life-years, and cost US dollars (USD) 45,032 per patient. The monotherapy gave 13.9 quality-adjusted life-years, and had a cost of USD 52,064. The incremental cost-effectiveness ratio of the monotherapy (USD −3,755 per quality-adjusted life-year) did not obtain extended dominance over combination therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most cost-effective option was combination therapy among patients with hepatitis B surface antigen levels of ≤10 IU/mL, which had the lowest calculated cost of USD 35,318 and most quality-adjusted life-years (16.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Below the WTP threshold of USD 29,250 (RMB 193,562, three times the domestic GDP per capita in 2018) per QALY, the combination treatment became more cost-effective compared with NA monotherapy as WTP increased” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line pegylated interferon alfa-2a with a week-12 stopping rule followed by tenofovir disoproxil fumarate or entecavir versus nucleos(t)ide analogue alone in HBeAg-negative chronic hepatitis B, Italy: Iannazzo et al. (2013)
Relevance: Evaluates first-line pegylated interferon alfa-2a with an early HBV DNA and HBsAg stopping rule, followed by a switch to entecavir or tenofovir disoproxil fumarate, against nucleos(t)ide analogue treatment alone in HBeAg-negative chronic hepatitis B in Italy, a finite interferon course in a model with an HBsAg clearance state.
Access: Free full text
Not quoted: The perspective, discount rate, and the ratio for each comparison are reported in the full text, which the publisher provides as a PDF that this page does not quote.
“We assessed the cost-effectiveness of week-12 HBV DNA/HBsAg stopping rule for early interruption and switch to currently most effective NA treatments (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A decision-analytic Markov model was developed in the following health-related states: CHB, compensated cirrhosis (CC) and decompensated cirrhosis, hepatocellular carcinoma, liver transplant, post-liver transplant, death, virological response, relapse and HBsAg clearance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Simulated strategies included: ETV/TDF in CHB; ETV/TDF delayed until CC; first-line PEG-IFN followed by switch to ETV/TDF for either patients meeting the week-12 stopping rule or week-48 null-responders/relapsers; and first-line PEG-IFN followed by switch to ETV/TDF delayed until CC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A lifetime simulation horizon was applied.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Early treatment strategies using NAs with or without first-line PEG-IFN provided the highest results (approximately 22 life-years and 15 quality-adjusted life years [QALYs]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average per-patient lifetime costs ranged from €33,500 (TDF in CC) to €68,900 (TDF in CHB). Costs using ETV were 20-50% higher. First-line PEG-IFN strategies ranged from dominant (that is, more effective and less costly) to highly cost-effective, although differences in QALYs were always very narrow.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Antiviral treatment sequences of pegylated interferon alfa-2a, tenofovir disoproxil fumarate, entecavir, and lamivudine versus no treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B, United Kingdom: Bermingham et al. (2015)
Relevance: Evaluates sequences of pegylated interferon alfa-2a, entecavir, tenofovir, and lamivudine in HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom, covering the nucleos(t)ide analogues and the pegylated interferon alfa listed in section 2 as current treatment options.
Access: Free full text
Tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir treatment sequences in HBeAg-positive and HBeAg-negative chronic hepatitis B, Canada: Tian et al. (2020)
Relevance: Evaluates tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir strategies in chronic hepatitis B in Canada, covering the nucleos(t)ide analogues listed in section 2 as current treatment options.
Access: Not open access
Not quoted: The discount rate and the results for the other treatment sequences are reported in the full text, which this page does not quote.
“We evaluated the cost effectiveness of TAF and other available treatment options for hepatitis B envelope antigen (HBeAg)-positive and HBeAg-negative CHB patients from a Canadian provincial Ministry of Health perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A state-transition model based on the published literature was developed to compare treatment strategies involving entecavir (ETV), tenofovir disoproxil fumarate (TDF), and TAF. It adopted a lifetime time horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For HBeAg-positive patients, TAF followed by ETV generated an additional 0.16 QALYs/person at an additional cost of Can$14,836.18 with an ICER of Can$94,142.71/QALY compared with TDF followed by ETV. Of the iterations, 28.7% showed that it is the optimal strategy with a Can$50,000 willingness-to-pay threshold.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For HBeAg-negative patients, ETV followed by TAF would prevent an additional 13 liver-related deaths per 1000 CHB patients compared with TDF, followed by ETV. It generated an additional 0.13 QALYs/person at an additional cost of Can$59,776.53 with an ICER of Can$461,162.21/QALY compared with TDF, followed by ETV.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our analysis suggests that TAF is not cost effective at its current cost. A 33.4% reduction in price would be required to make it cost effective for HBeAg-positive patients with a Can$50,000 willingness-to-pay threshold.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response-guided peginterferon with a 12-week stopping rule, 48-week peginterferon, entecavir, tenofovir, and telbivudine versus no treatment in chronic hepatitis B, Hong Kong: Lo et al. (2015)
Relevance: Compares response-guided pegylated interferon with an early stopping rule and a conventional pegylated interferon course with entecavir, tenofovir, and telbivudine in chronic hepatitis B in Hong Kong, setting a finite treatment course against continuous nucleos(t)ide analogue therapy.
Access: Free full text
Entecavir, lamivudine, and adefovir by treatment duration in HBeAg-negative chronic hepatitis B, United States: Veenstra et al. (2008)
Relevance: Evaluates the choice of nucleos(t)ide analogue and the duration of treatment, including fixed courses and on-off schedules, in HBeAg-negative chronic hepatitis B in the United States, bearing on the nucleos(t)ide analogue withdrawal described in section 2.
Access: Not open access
Not quoted: The discount rate and the results for the other comparisons of drugs and durations are reported in the full text, which this page does not quote.
“We conducted a cost-utility analysis from a payer perspective over a lifetime time horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Disease progression probabilities, costs and quality of life data were derived from the literature.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We evaluated 5-year, 10-year, lifetime and 5 on-1 off treatment durations. For each of these treatment durations, we evaluated initial therapy with entecavir, lamivudine or adefovir, with addition of adefovir or entecavir for patients who developed virological breakthrough because of resistance (12 strategies total).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing treatment duration improved quality-adjusted life-years (QALYs) and was generally cost-effective for all three drugs. However, a 5 on-1 off strategy was the most cost-effective: lifetime vs. 5 on-1 off entecavir had an ICER of $148,200/QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In probabilistic sensitivity analyses, entecavir 5 on-1 off was the preferred strategy over the range of commonly reimbursed cost-effectiveness thresholds.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lifetime treatment was preferred to a 5 on-1 off strategy, if treatment durability was < 10%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Initial entecavir, pegylated interferon, telbivudine, lamivudine, or adefovir with follow-up therapy versus no treatment in HBeAg-positive chronic hepatitis B, United States: Spackman and Veenstra (2008)
Relevance: Evaluates initial entecavir, lamivudine, telbivudine, adefovir, and pegylated interferon strategies with follow-up therapy in HBeAg-positive chronic hepatitis B in the United States, a model whose health states include HBsAg loss and hepatic flare.
Access: Not open access
Not quoted: The incremental cost-effectiveness ratios for each comparison are reported in the full text, which is closed access.
“We conducted a cost-utility analysis from a US payer perspective over a lifetime time horizon using a Markov model, in a hypothetical population with HBeAg-positive CHB and a mean age of 35 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We assumed a treatment duration of 4 years, with the use of combination therapy for drug resistance. Nonresponders to pegylated interferon were assumed to receive entecavir in years 3-4.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were valued in $US, year 2008 values. Costs and outcomes were discounted at 3% per annum.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Initiation with entecavir (18.70 QALYs) and pegylated interferon (18.64 QALYs) provided the largest treatment benefits overall, followed by telbivudine (18.55 QALYs).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The probabilities of the interventions being cost effective at a threshold of USD 50,000 per QALY were 57%, 37% and 2% for initiation with entecavir, pegylated interferon and telbivudine, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
The same disease in other populations or settings
Increased monitoring and treatment versus current practice in inactive or immune-tolerant chronic hepatitis B, United States: Toy et al. (2025)
Relevance: Evaluates increased monitoring and treatment, and the addition of liver cancer surveillance, among adults with inactive or immune-tolerant chronic hepatitis B without cirrhosis in the United States from a health care system perspective, in a model with HBsAg seroclearance and viral suppression health states.
“A Markov model was used to calculate the costs, health impact and cost-effectiveness of increased monitoring of adults with HBeAg negative inactive or HBeAg positive immune tolerant CHB who have no cirrhosis or significant fibrosis and are not recommended by the current American Association for the Study of Liver Diseases (AASLD) clinical practice guidelines to receive antiviral treatment, and to assess whether the addition of HCC surveillance would be cost-effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease progression between health states, conditional on treatment, age (where available) and sex was simulated in one-year cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs and QALYs were discounted at a rate of 3% per year. The analysis was performed from the health care system perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to current practice, where an estimated 37% of persons with inactive or immune tolerant CHB are monitored and 59% receiving antiviral therapy when they become treatment eligible, increased monitoring to 90% and treatment to 80%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regular monitoring of persons with inactive or immune tolerant CHB who are initially not recommended to receive antiviral treatment in the United States is cost-saving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For every 100,000 persons with inactive or immune active CHB, increasing monitoring to 90% and antiviral treatment for eligible individuals to 80% would save $180 million in lifetime health care costs, add 45,100 QALYs and would avert 4,590 cases of cirrhosis, 1,500 cases of decompensated cirrhosis, 2,450 cases of HCC, and 4,700 HBV related deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At a willingness to pay threshold of $100,000/QALY, the addition of HCC surveillance with the standard recommended biannual liver ultrasound and alfa fetoprotein levels is likely cost-effective if the HCC risk ≥ 0.55%/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
One-time universal hepatitis B screening with monitoring and treatment versus current practice in adults, United States: Toy et al. (2022)
Relevance: Evaluates one-time universal hepatitis B surface antigen screening of adults, followed by monitoring and treatment, against current practice in the United States, a model of progression of chronic hepatitis B to cirrhosis and hepatocellular carcinoma.
Access: Free full text
Biannual or annual hepatocellular carcinoma surveillance versus no surveillance in chronic hepatitis B with virological remission, China: Fang et al. (2024)
Relevance: Evaluates hepatocellular carcinoma surveillance schedules in chronic hepatitis B with virological remission in China, the virally suppressed state on nucleos(t)ide analogue therapy that the bepirovirsen label requires; the ratios shown are those for the advanced fibrosis group.
“We developed an individual-based state transition model, simulating the advancement of HCC in CHB patients with virological remission. We used this model to compare the incremental cost-effectiveness ratio (ICER) and long-term health outcomes of biannual or annual HCC surveillance for varying durations with no surveillance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The baseline population consisted of a cohort of 100,000 CHB patients aged 40 to 70 years (with a greater risk of developing HCC)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By altering the duration of surveillance in increments of 5 years from 10 years to lifetime, we simulated various HCC surveillance strategies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The costs were converted to US dollars using the exchange rates applicable in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We applied a 3% yearly discount rate to all future costs and QALYs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study revealed that conducting biannual surveillance for advanced fibrosis in individuals aged 40 had the most favorable incremental cost-effectiveness ratio (ICER) when discontinuing surveillance at the age of 65. This approach was associated with an ICER of USD 4,760/QALY gained. Conversely, the highest ICER was identified when surveillance was discontinued at 50 years of age, leading to a cost of USD 18,900 per QALY gained. Surveillance up to age 75 (USD 12,970/QALY gained) provided most QALY gains of 0.67 at an additional cost of USD 6,446 and was the most cost-effective strategy, with an ICER below the WTP threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the case of 40-year-old patients with advanced fibrosis, the ICER of annual surveillance was found to be the lowest when the surveillance was discontinued at the age of 60, with an ICER of USD 2,759 per QALY gained, and was highest when the stopping age was 55 (USD 34,363/QALY gained), which was not cost-effective with the ICERs exceeding the WTP threshold (USD 32,268/QALY gained).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with advanced fibrosis, compared with no surveillance, biannual (Fig. 2C) and annual (Fig. 2D) surveillance for any age group were nondominated. Surveillance targeting those aged 40–75 was the most cost-effective strategy, either biannual (USD 12,970/QALY gained) or annual (USD 4,984/QALY gained) surveillance intervals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nucleos(t)ide analogue therapy versus no treatment in untreated minimally active chronic hepatitis B, South Korea: Lee et al. (2021)
Relevance: Evaluates nucleos(t)ide analogue therapy against no treatment in untreated minimally active chronic hepatitis B in South Korea from a health care system perspective, in a model that includes disutilities for kidney and bone adverse events of nucleos(t)ide analogues.
“We compared cost and effectiveness (quality-adjusted life years, QALYs) in virtual UMA-CHB cohorts of 10,000 50-year-olds receiving AVT (scenario 1) vs no treatment (scenario 2) for 10 years. A Markov model, including 7 health states of CHB-related disease progression, was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An analytic period of 10 years was used in the base-case analysis, which was conducted from the perspective of the health care system. A 5% discount rate was used for the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From the health care system perspective, all estimated costs for each health state included direct and indirect costs such as transportation and caregiving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total cost per patient over the 10-year horizon was estimated at $15,349 for the NUC therapy group (scenario 1) and $13,148 for the no treatment group, yielding a difference of $2,201.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The simulation of AVT vs no treatment predicted $2,201 incremental costs and 0.175 incremental QALYs per patient for 10 years, with an incremental cost-effectiveness ratio (ICER) of $12,607/QALY, suggesting cost-effectiveness of AVT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the simulated analysis period was extended to 20 years, AVT was also highly cost-effective with an ICER of $2,036/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to probabilistic sensitivity analysis with the threshold of willingness to pay, the probability of AVT cost-effectiveness was 83.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Related diseases and analogous treatments
No evidence found.
Utility weights
Utility weights from analyses of Hibsago (bepirovirsen and GSK3228836)
No evidence found.
Utility weights for the same indication
Utility weights for chronic hepatitis B, HBeAg seroconversion, HBsAg loss, flare, resistance, cirrhosis, hepatocellular carcinoma, and liver transplantation, HBeAg-negative chronic hepatitis B: Veenstra et al. (2008)
Relevance: Utilities for chronic hepatitis B, HBeAg seroconversion, HBsAg loss, hepatic flare, drug resistance, cirrhosis states, hepatocellular carcinoma, and liver transplantation from a U.S. analysis of nucleos(t)ide analogue treatment duration.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which this page does not quote.
Utility weights for chronic hepatitis B, HBeAg seroconversion, HBsAg loss, flare, resistance, cirrhosis, hepatocellular carcinoma, liver transplant, and pegylated interferon treatment, HBeAg-positive chronic hepatitis B: Spackman and Veenstra (2008)
Relevance: Utilities for chronic hepatitis B, HBeAg seroconversion, HBsAg loss, flare, treatment resistance, cirrhosis states, hepatocellular carcinoma, and liver transplantation, and a disutility during pegylated interferon treatment, from a U.S. analysis.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
Utility weights for chronic hepatitis B, virological response, HBsAg clearance, cirrhosis, hepatocellular carcinoma, and liver transplant, HBeAg-negative chronic hepatitis B: Iannazzo et al. (2013)
Relevance: Utilities for chronic hepatitis B, virological response, HBsAg clearance, compensated and decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation in HBeAg-negative chronic hepatitis B.
Access: Free full text
Not quoted: The utility weights are reported in the full text, which the publisher provides as a PDF that this page does not quote.
“A decision-analytic Markov model was developed in the following health-related states: CHB, compensated cirrhosis (CC) and decompensated cirrhosis, hepatocellular carcinoma, liver transplant, post-liver transplant, death, virological response, relapse and HBsAg clearance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights for HBsAg loss, chronic hepatitis B, cirrhosis, liver transplantation, and hepatocellular carcinoma, chronic hepatitis B: Li et al. (2021)
Relevance: Utilities for an HBsAg state, chronic hepatitis B, compensated and decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation in HBeAg-negative chronic hepatitis B treated with nucleos(t)ide analogues.
Utility weights for chronic hepatitis B, decompensated cirrhosis, hepatocellular carcinoma, post-transplant, hepatic flare, and peginterferon treatment, chronic hepatitis B: Lo et al. (2015)
Relevance: Utilities for chronic hepatitis B, decompensated cirrhosis, hepatocellular carcinoma, post-transplant, hepatic flare, and pegylated interferon treatment, including the hepatic flare state that the bepirovirsen boxed warning names.
Access: Free full text
Utility weights for HBsAg seroconversion, active chronic hepatitis B, viral suppression, cirrhosis, hepatocellular carcinoma, and liver transplant, chronic hepatitis B: Bermingham et al. (2015)
Relevance: Utilities for HBsAg seroconversion, active chronic hepatitis B, viral suppression, cirrhosis states, hepatocellular carcinoma, and liver transplantation from the United Kingdom analysis of antiviral sequences.
Access: Free full text
Utility weights for chronic hepatitis B, cirrhosis, hepatocellular carcinoma, and post-liver transplant, chronic hepatitis B: Lin et al. (2025)
Relevance: EQ-5D utilities for chronic hepatitis B, compensated and decompensated cirrhosis, hepatocellular carcinoma, and post-liver transplant in an analysis of nucleos(t)ide analogues in China.
Utility weights for the same disease in other populations or settings
Utility weights for chronic hepatitis B by disease state, viral suppression, and HBsAg seroclearance, chronic hepatitis B: Toy et al. (2025)
Relevance: Utilities by chronic hepatitis B state, including inactive disease, viral suppression, HBsAg seroclearance, cirrhosis, decompensated cirrhosis, hepatocellular carcinoma by mode of detection, and liver transplantation, used in a United States model.
Utility weights for active chronic hepatitis B, cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation, chronic hepatitis B: Toy et al. (2022)
Relevance: Utilities for active chronic hepatitis B, cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation, used in a United States model of universal hepatitis B screening.
Access: Free full text
Utility weights for minimally active chronic hepatitis B, liver disease states, and adverse events of nucleos(t)ide analogue therapy, chronic hepatitis B: Lee et al. (2021)
Relevance: Utilities for minimally active chronic hepatitis B, virological response, cirrhosis states, hepatocellular carcinoma, and liver transplantation, with disutilities for chronic kidney disease, osteopenia, and osteoporosis as adverse events of nucleos(t)ide analogue therapy.
Utility weights for related diseases and analogous treatments
No evidence found.
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Ratios | bepirovirsen OR GSK3228836 | 0 |
| Methods | bepirovirsen | 0 |
| Methods | "functional cure" AND "hepatitis B" | 1 |
| Ratios | "chronic hepatitis B" AND (tenofovir OR entecavir) | 333 |
| Methods | "hepatitis B" | 223 |
| Methods | HBV | 113 |
| Ratios | "HBsAg" OR "functional cure" OR "HBsAg loss" OR "seroclearance" | 131 |
| Weights | "hepatitis B" | 1015 |
| Weights | "surface antigen" OR "HBsAg" OR "seroclearance" OR "functional cure" | 217 |
| Ratios | "hepatitis B" AND (peginterferon OR "pegylated interferon" OR "peg-interferon" OR "PEG-IFN") | 121 |
| Ratios | "hepatitis B" AND (discontinuation OR stopping OR "finite" OR withdrawal OR "duration") | 63 |
| Ratios | antisense OR inotersen OR eplontersen OR mipomersen OR olezarsen | 4 |
| Methods | "hepatitis C" AND ledipasvir AND "United States" | 4 |
| Weights | "thrombocytopenia" AND "hepatitis" | 9 |
| Weights | "hepatitis B" AND flare | 5 |